Boston Scientific (NYSE:BSX) Price Target Lowered to $115.00 at Royal Bank Of Canada

Boston Scientific (NYSE:BSX) had its price objective cut by Royal Bank Of Canada from $130.00 to $115.00 in a report issued on Thursday, MarketBeat reports. They currently have an outperform rating on the medical equipment provider’s stock.

A number of other analysts have also recently issued reports on BSX. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, January 21st. Oppenheimer reduced their price objective on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research note on Friday, January 16th. TD Cowen decreased their price objective on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a report on Monday. Truist Financial cut their target price on Boston Scientific from $120.00 to $95.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $109.32.

Boston Scientific Price Performance

BSX opened at $77.60 on Thursday. The stock has a fifty day moving average price of $93.90 and a 200 day moving average price of $98.98. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. Boston Scientific has a 1 year low of $74.86 and a 1 year high of $109.50. The stock has a market cap of $115.04 billion, a price-to-earnings ratio of 40.00, a PEG ratio of 1.33 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.The business’s quarterly revenue was up 15.9% on a year-over-year basis. During the same period last year, the business earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts forecast that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Boston Scientific

Several large investors have recently bought and sold shares of the stock. Norges Bank acquired a new stake in Boston Scientific in the 2nd quarter worth $2,089,937,000. Edgewood Management LLC bought a new stake in shares of Boston Scientific in the second quarter valued at about $746,655,000. Parnassus Investments LLC grew its position in Boston Scientific by 42,978.9% during the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after buying an additional 6,868,459 shares in the last quarter. Egerton Capital UK LLP increased its stake in Boston Scientific by 223.7% during the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after acquiring an additional 3,671,548 shares during the period. Finally, Bessemer Group Inc. raised its holdings in Boston Scientific by 14,391.8% in the 2nd quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock valued at $313,618,000 after acquiring an additional 2,899,653 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 results beat Wall Street: Boston Scientific reported $0.80 EPS and $5.29B in sales (sales +15.9%), showing solid underlying growth that supports the company’s long-term story. PR: Q4 results
• Positive Sentiment: Analysts still mostly constructive: Many firms kept buy/overweight ratings and continue to model meaningful upside even after trimming forecasts — that backing can attract buyers after the drop. Benzinga: analysts cutting forecasts
• Neutral Sentiment: Planned board departure announced — a governance change (long‑serving director stepping down) that is notable but not an operational shock. TipRanks: board departure
• Neutral Sentiment: Unusual options activity and heavy put buying increased volatility — option flows amplified the move and can accelerate selloffs or rebounds depending on market makers’ hedging. Barchart: options activity
• Negative Sentiment: Soft 2026 guidance and underperformance in electrophysiology: management gave a cautious revenue/quarterly outlook and flagged weaker EP sales, which triggered the earlier large selloff as it reset near-term growth expectations. Reuters: cautious outlook
• Negative Sentiment: Multiple price-target cuts: several banks trimmed targets (some steeply) after the print — that lowers analyst floor and can weigh on recovery momentum. Benzinga: PT cuts
• Negative Sentiment: New investor class-action inquiry: Levi & Korsinsky announced an investigation into BSX related to the Feb. 4 results, which is a legal overhang until resolved. Newsfile: securities probe
• Negative Sentiment: CEO insider sale disclosed (large block sold in early Feb.) — raises near‑term sentiment concerns even if not unusual for executives. SEC filing: insider sale

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.